Regulatory

May 27, 2025

Report from Annual General Meeting in Affibody Medical AB (publ)

Stockholm, Sweden, May 27, 2025 – Affibody Medical AB (publ) today held its Annual General Meeting. The following resolutions were adopted. Adoption of the income statement and the balance...

Read more

News

April 29, 2025

Positive Phase 2 Clinical Results for Izokibep in Psoriatic Arthritis Published

Solna, Sweden, April 29, 2025. Affibody AB (“Affibody”) today announced that a publication outlining the positive results from a Phase 2 clinical study with izokibep, a next generation IL-17...

Read more

Regulatory

April 25, 2025

NOTICE OF ANNUAL GENERAL MEETING IN AFFIBODY MEDICAL AB (PUBL)

The shareholders of Affibody Medical AB (publ), corporate identity number 556714-5601 (the “Company” or “Affibody”) are hereby invited to attend the annual general meeting of the shareholders on Tuesday...

Read more

News

February 2, 2025

Affibody regains worldwide rights to izokibep

Stockholm, Sweden, February 2, 2025. Affibody today announced that the company will regain all rights to izokibep. In 2021, Affibody and ACELYRIN, INC. entered into a license and collaboration...

Read more

News

January 15, 2025

Additional data from Affibody’s HER2 radiopharmaceutical program presented at PepTalk

Affibody AB (“Affibody”) announces presentation of data from IND enabling preclinical studies with the radiotherapeutic agent 177Lu-ABY-271 for treatment of HER2 expressing metastatic disease. The data will be presented...

Read more

News

January 10, 2025

Affibody regains rights in selected Asian countries to izokibep

Stockholm, Sweden, January 10, 2025. Affibody today announced that the company has regained rights to izokibep in selected Asian countries. In 2020, Affibody and Inmagene Biopharmaceuticals entered into a...

Read more

News

January 7, 2025

Affibody’s Nomination Committee for the 2025 Annual General Meeting

Stockholm, Sweden, January 7, 2025. Affibody Medical AB (publ) today announced the composition of the Nomination Committee for the 2025 Annual General Meeting (AGM) to be held on May...

Read more

Regulatory

December 10, 2024

Affibody’s Licensee ACELYRIN Announces Top-line Results for Izokibep in Uveitis

Stockholm, Sweden, December 10, 2024. Affibody’s licensee ACELYRIN, INC. today announced that the Phase 2b/3 trial of izokibep in non-infectious, non-anterior uveitis did not meet the primary endpoint. Izokibep...

Read more

News

October 20, 2024

Data demonstrating pre-clinical efficacy and safety of Affibody’s radio-therapeutic anti-HER2 agent ABY-271 presented at EANM annual congress

Affibody AB (“Affibody”) announces presentation of data from IND enabling preclinical studies with the radiotherapeutic agent 177Lu-ABY-271 for treatment of HER2 expressing metastatic disease. The data will be presented...

Read more